New hope for hard-to-treat colorectal cancer: triple therapy enters phase 2 trial
Disease control
Recruiting now
This study tests a new oral drug (SR-8541A) combined with two immunotherapy drugs for people with advanced colorectal cancer that has spread and no longer responds to standard chemotherapy. The trial aims to find the best dose and check if the combination is safe and effective. A…
Phase: PHASE2 • Sponsor: Stingray Therapeutics • Aim: Disease control
Last updated May 18, 2026 06:35 UTC